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The TLR9 Ligand, CpG-ODN, Induces Protection against Cerebral
Ischemia/Reperfusion Injury via Activation of PI3K/Akt Signaling
Chen Lu, MD; Tuanzhu Ha, MD; Xiaohui Wang, MS; Li Liu, MD; Xia Zhang, MD; Erinmarie Olson Kimbrough, BS; Zhanxin Sha, MS;
Meijian Guan, BS; John Schweitzer, MD; John Kalbﬂeisch, PhD; David Williams, PhD; Chuanfu Li, MD

Background-—Toll-like receptors (TLRs) have been shown to be involved in cerebral ischemia/reperfusion (I/R) injury. TLR9 is
located in intracellular compartments and recognizes CpG-DNA. This study examined the effect of CpG-ODN on cerebral I/R
injury.
Methods and Results-—C57BL/6 mice were treated with CpG-ODN by i.p. injection 1 hour before the mice were subjected to
cerebral ischemia (60 minutes) followed by reperfusion (24 hours). Scrambled-ODN served as control-ODN. Untreated mice,
subjected to cerebral I/R, served as I/R control. The effect of inhibitory CpG-ODN (iCpG-ODN) on cerebral I/R injury was also
examined. In addition, we examined the therapeutic effect of CpG-ODN on cerebral I/R injury by administration of CpG-ODN
15 minutes after cerebral ischemia. CpG-ODN administration signiﬁcantly decreased cerebral I/R-induced infarct volume by 69.7%
(6.41.80% vs 21.02.85%, P<0.05), improved neurological scores, and increased survival rate, when compared with the
untreated I/R group. Therapeutic administration of CpG-ODN also signiﬁcantly reduced infarct volume by 44.7% (12.62.03% vs
22.82.54%, P<0.05) compared with untreated I/R mice. Neither control-ODN, nor iCpG-ODN altered I/R-induced cerebral injury
or neurological deﬁcits. Nissl staining showed that CpG-ODN treatment preserved neuronal morphology in the ischemic
hippocampus. Immunoblot showed that CpG-ODN administration increased Bcl-2 levels by 41% and attenuated I/R-increased
levels of Bax and caspase-3 activity in ischemic brain tissues. Importantly, CpG-ODN treatment induced Akt and GSK-3b
phosphorylation in brain tissue and cultured microglial cells. PI3K inhibition with LY294002 abolished CpG-ODN-induced
protection.
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Conclusion-—CpG-ODN signiﬁcantly reduces cerebral I/R injury via a PI3K/Akt-dependent mechanism. Our data also indicate that
CpG-ODN may be useful in the therapy of cerebral I/R injury. ( J Am Heart Assoc. 2014;3:e000629 doi: 10.1161/
JAHA.113.000629)
Key Words: apoptosis • cerebral ischemia/reperfusion injury • CpG-ODN • toll-like receptors

S

troke is the third leading cause of death and the leading
cause of long-term disability in the United States. About
795 000 Americans suffer a new or recurrent stroke annually.1 Approximately 610 000 of these are ﬁrst attacks and
185 000 are recurrent attacks.1 Cerebral ischemia/reperfusion (I/R) injury (ischemic stroke) accounts for about 83% of
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all stroke cases.1 At present, there is no effective treatment
for cerebral I/R injury. Numerous studies have demonstrated
that the innate immune and inﬂammatory responses mediated
by Toll-like receptors (TLRs) play an important role in cerebral
ischemia/reperfusion (I/R) injury.2–4 TLRs are pattern recognition receptors that play a critical role in the induction of
innate immune and inﬂammatory responses.5 Recent evidence suggests that TLRs may be the important targets for
development of new treatment approaches for cerebral I/R
injury.6–10 We have demonstrated that TLR4 deﬁciency or
TLR2 modulation signiﬁcantly attenuates brain injury in
response to cerebral I/R.10–12 Published data have also
shown that TLR agonists attenuate cerebral I/R injury through
a preconditioning mechanism.9,13–15
TLR9 is located intracellularly in endosomes and endoplasmic reticulum.16 TLR9 recognizes unmethylated CpG-DNA
from bacteria and endogenous DNA.16 Synthetic CpGoligodeoxynucleotide (ODN) has been reported to activate
TLR9,16,17 improve cell survival, prevent cell apoptosis,18
Journal of the American Heart Association
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Materials and Methods
Animals
Male C57BL/6 mice were purchased from The Jackson
Laboratory. The mice were maintained in the Division of
Laboratory Animal Resources at East Tennessee State
University (ETSU). The experiments outlined in this article
conform to the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health (NIH
Publication, eighth Edition, 2011). All aspects of the animal
care and experimental protocols were approved by the ETSU
Committee on Animal Care.

Focal cerebral ischemia/reperfusion
Focal cerebral I/R was induced by occlusion of the middle
cerebral artery (MCAO) on the left side as described in our
previous studies.9,10,30,31 Brieﬂy, mice (23 to 25 g body
weight) were anesthetized by 5.0% Isoﬂurane and anesthesia
was maintained by inhalation of 1.5% to 2% Isoﬂurane driven
by 100% oxygen ﬂow. Mice were intubated and ventilated
using a rodent ventilator at a rate of 110 breaths/minute
DOI: 10.1161/JAHA.113.000629

with a total delivered volume of 0.5 mL. Body temperature
was regulated at 37°C by surface water heating. Following
the skin incision, the left common carotid artery (CCA), the
external carotid artery (ECA) and the internal carotid artery
(ICA) were carefully exposed. Microvascular aneurysm clips
were applied to the left CCA and the ICA. A coated 6-0
ﬁlament (6023PK; Doccol Corp) was introduced into an
arteriotomy hole, fed distally into the ICA. After the ICA
clamp was removed, the ﬁlament was advanced 11 mm
from the carotid bifurcation, and focal cerebral ischemia
started. After ischemia for 60 minutes, the ﬁlament and the
CCA clamp were gently removed (reperfusion starts). The
collar suture at the base of the ECA stump was tightened.
The skin was closed, anesthesia discontinued, and the
animal allowed to recover in pre-warmed cages. Control
mice underwent a neck dissection and coagulation of the
external carotid artery, but no occlusion of the middle
cerebral artery.

Measurement of cerebral blood ﬂow
Successful occlusion of the middle cerebral artery was
veriﬁed and recorded by laser-Doppler ﬂowmetry (Model
PeriFlux System 5000; Perimed) as described previously.30
Brieﬂy, under anesthesia, a midline incision of the head was
made and a probe holder was attached to the skull with crazy
glue at 6 mm lateral and 1 mm posterior to the bregma. A
laser-Doppler probe was connected to the probe holder, and
regional cerebral blood ﬂow (CBF) was monitored and
recorded. The data was retrieved continuously, stored in a
computer, and analyzed using the Perimed data acquisition
and analysis system. Regional CBF was expressed as a
percentage of preischemic baseline values.

Experimental Design
To examine the role of CpG-ODN on focal cerebral I/R injury,
mice were treated with CpG-ODN (10 lg/25 g body weight)
or control-ODN (n=8, 10 lg/25 g body weight) by intraperitoneal injection (i.p.) 1 hour prior to cerebral ischemia
(60 minutes) followed by reperfusion.
To evaluate the effect of TLR9 inhibition on cerebral I/R
injury, we chose inhibitory CpG-ODN (iCpG-ODN), which
binds C-terminal fragment of TLR9 preventing TLR9 activation.32 iCpG-ODN (n=8, 100 lg/25 g body weight) was
administered to mice by i.p. injection 1 hour prior to focal
cerebral I/R. Mice that did not receive any treatment
served as untreated controls. The CpG-ODN (CpG-ODN
1826), Control-ODN (control-ODN 1826), and iCpG-ODN
(iCpG-ODN 2088) were purchased from InvivoGen and
dissolved in sterile endotoxin-free water.20,23
To examine the therapeutic effect of CpG-ODN on focal
cerebral I/R injury, CpG-ODN was administered to mice
Journal of the American Heart Association
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attenuate cardiac dysfunction after I/R19,20 and improve
outcome in shock induced by polymicrobial sepsis21–23 or
trauma hemorrhage.24 Scholtzova et al reported that administration of CpG-ODN effectively ameliorated Alzheimer’s
disease-related pathophysiology.25 Stevens et al reported
pretreatment of animals with CpG-ODN for 24 hours induced
neuroprotection against ischemic injury through a preconditioning mechanism.14 Because preconditioning requires a
prolonged pretreatment time, it is important to investigate
whether therapeutic administration of CpG-ODN will attenuate
cerebral I/R injury.
Phosphoinositide 3-kinases (PI3Ks) and their downstream
target serine/threonine kinase Akt are a conserved family of
signal transduction enzymes that are involved in regulating
cellular activation, inﬂammatory responses, and apoptosis.26
Activation of PI3K/Akt-dependent signaling plays a role in
protection against organ injury in response to I/R,20,27,28
septic shock23 as well as trauma hemorrhage.24 Recent
evidence has also shown cross talk between PI3K/Akt
signaling and TLR-mediated pathways.20,23,29 We have
previously reported that activation of PI3K/Akt signaling
contributes to the protection against cerebral I/R injury by
modulation of TLR2.30
The goal of the present study was to investigate the
effect of CpG-ODN on cerebral I/R injury. We observed
that CpG-ODN administration signiﬁcantly reduced infarct
volume and improved neurological functional recovery
after cerebral I/R injury. Therapeutic administration of
CpG-ODN also markedly decreased infarct volume following
cerebral I/R.

CpG-ODN Decreases Cerebral Ischemic Injury
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Measurement of infarct volume

Downloaded from http://ahajournals.org by on March 29, 2022

The infarct volume was determined as described previously.9,10,30,31 The infarct volume was measured by one
blinded to experimental group. After completion of reperfusion, mice were sacriﬁced and perfused with ice-cold
phosphate buffered saline (PBS) via the ascending aorta.
Brains were removed and sectioned coronally into 2-mm-thick
slices. The slices were stained with 2% triphenyltetrazolium
chloride (TTC) solution at 37°C for 15 minutes followed by
ﬁxation with 10% formalin neutral buffer solution (pH 7.4). The
infarct areas were traced and quantiﬁed with an imageanalysis system. Unstained areas (pale color) were deﬁned as
ischemic lesions. The areas of infarction and the areas of both
hemispheres were calculated for each brain slice. An edema
index was calculated by dividing the total volume of the left
hemisphere by the total volume of the right hemisphere. The
actual infarct volume adjusted for edema was calculated by
dividing the infarct volume by the edema index.9,10,30,31
Infarct volumes are expressed as a percentage of the total
brain volumeSEM.

Evaluation of neuronal damage in the hippocampal
formation (HF)
Neuronal damage in brain sections was examined by Nissl
staining as described previously.9,10,30,31 Parafﬁn sections cut
in the coronal plane at approximately 1.5 mm behind bregma
with a thickness of 7 microns were deparafﬁnized and then
stained with 0.1% cresyl violet for 2 minutes. The sections
were evaluated using light microscopy.

Evaluation of neurological score
Neurological score was performed by a blinded investigator
using a neurological evaluation instrument described in our
previous studies.9,30 The neurological score was evaluated by
one blinded to experimental group. Brieﬂy, the scoring system
included 5 principle tasks: spontaneous activity over a 3minute period (0 to 3), symmetry of movement (0 to 3), openDOI: 10.1161/JAHA.113.000629

ﬁeld path linearity (0 to 3), beam walking on a 3 cm91 cm
beam (0 to 3), and response to vibrissae touch (1 to 3). The
scoring system ranged from 0 to 15, in which 15 is a perfect
score and 0 is death due to cerebral I/R injury. Sham controls
received a score of 15.

In situ apoptosis assay
In situ neuronal cell apoptosis was examined by the TdTmediated dUTP nick end-labeling (TUNEL) assay (Roche
Applied Science) as described previously.30 Fields of hippocampus were randomly evaluated for the percentage of
apoptotic cells using the TUNEL assay. The images were
viewed on an EVOS-ﬂ digital inverted ﬂuorescent microscopy
(Advanced Microscopy Group). Total cells were counted in
each ﬁeld, and apoptotic cells are presented as the percentage of total cells counted.

Immunohistochemistry ﬂuorescent staining
Fluorescent staining was performed to examine caspase-3
activity and microglia activation after cerebral I/R as
described previously.30 Brieﬂy, brains from each group were
harvested and immersion-ﬁxed in 4% buffered parafomaldehyde, embedded in parafﬁn, cut at 7 lm, and stained with
an speciﬁc anti-cleaved caspase-3 antibody (Cell Signaling
Technology, Inc) or anti-Iba-1 antibody (Santa Cruz Biotechnology, Inc) as described previously.30 After washing, the
tissue sections were incubated with FITC-conjugated antirabbit (GeneTex) for 1 hour at 25°C and covered with
ﬂuorescence mounting medium (Life Technologies). The
images were viewed on an EVOS-ﬂ digital inverted ﬂuorescent microscopy (Advanced Microscopy Group). Fields of
cortex were randomly examined using a deﬁned rectangular
ﬁeld area for analysis of microglia activation. Total cells
were counted in each ﬁeld, and Iba-1-positive activated
microglia cells are presented as the percentage of total cells
counted.

In vitro experiments
BV2 microglial cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) and penicillin
(Gibco) under 5% CO2 at 37°C.30 When BV2 cells reached 70%
to 80% conﬂuence, they were stimulated with CpG-ODN
(100 nmol/L) or Control-ODN (100 nmol/L), respectively,
under normoxic conditions for 15, 30, and 60 minutes. The
cells were harvested and cellular proteins were isolated for
examination of Akt and glycogen synthase kinase (GSK)-3b
phosphorylation by Western Blot.30,33,34
In separate experiments, BV2 cells were treated with CpGODN (100 nmol/L) for 15, 30, and 60 minutes in the
presence and absence of LY294002 (20 lmol/L). BV2 cells
were also treated with 20 lmol/L LY294002 for 60 minutes.
Journal of the American Heart Association
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15 minutes after focal cerebral ischemia (n=8) by i.p.
injection. Focal cerebral ischemia was continued for an
additional 45 minutes followed by reperfusion for 24 hours.
To evaluate the effect of CpG-ODN on cerebral functional
recovery and survival, CpG-ODN was administered to mice
1 hour prior to cerebral ischemia (60 minutes) followed by
reperfusion for up to 21 days.
To determine the role of PI3K/Akt signaling in CpG-ODN
induced protection against cerebral I/R injury, the PI3K
inhibitor LY294002 (1 mg/25 g body weight) was given to
mice 15 minutes before CpG-ODN administration. The mice
were subjected to focal cerebral ischemia (60 minutes)
followed by reperfusion (24 hours).
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Western blot
Cellular proteins were prepared from brain tissues and western
blots were performed as described previously.8–10,30,31 Brieﬂy,
the cellular proteins were separated by SDS-PAGE and
transferred onto Hybond ECL membranes (Amersham Pharmacia). The ECL membranes were incubated with the appropriate antibodies, respectively, (anti-phospho-Akt [Ser473],
anti-phospho-GSK-3b [Ser9], anti-Bax, anti-Cleaved Caspase-3
[Cell Signaling Technology], anti-Akt, anti-GSK-3b and anti-Bcl2
[Santa Cruz Biotechnology]) followed by incubation with
peroxidase-conjugated secondary Abs (Cell Signlaing Technology). The signals were detected with the ECL system (Amersham Pharmacia). To control for lane loading, the same
membrane were probed with anti-GAPDH (glyceraldehyde-3phosphate dehydrogenase, Biodesign) after being washed with
stripping buffer. The signals were quantiﬁed by scanning
densitometry using a Syngene G: Box Image Analysis System.

Caspase-3/7 activity assay
Caspase-3/7 activity in brain tissue was measured using a
Caspase-Glo assay kit (Promega) according to the manufacturer’s protocol as described previously.34
Downloaded from http://ahajournals.org by on March 29, 2022

Statistical Analysis
Data is presented in ﬁgures as meanSEM for experimental
groups. Group mean levels were compared with analysis of
variance (one-way or multifactorial as dictated by the design
structure) and the least signiﬁcant difference procedure (since
the F-test was statistically signiﬁcant). The log-rank test was
used to compare group survival trends (Kaplan-Meier plot in
Figure 2B). Probability levels of 0.05 or smaller were used to
indicate statistical signiﬁcance.

Results
CpG-ODN Administration Decreased Focal
Cerebral Infarct Volume Following I/R
To examine the role of CpG-ODN in focal cerebral I/R injury,
we administered CpG-ODN, control-ODN or iCpG-ODN to
mice 1 hour before the mice were subjected to cerebral
ischemia (1 hour) and reperfusion (24 hours). Figure 1A
shows that CpG-ODN administration signiﬁcantly reduced
infarct volume by 69.7% compared with the untreated I/R
group (6.41.80% vs 21.02.85%). Administration of either
control-ODN or iCpG-ODN to mice did not alter I/R-induced
cerebral infarct volume. We also evaluated the therapeutic
DOI: 10.1161/JAHA.113.000629

effect of CpG-ODN on cerebral I/R injury. As shown in
Figure 1B, therapeutic administration of CpG-ODN at 15 minutes after ischemia signiﬁcantly reduced infarct volume by
44.7%, when compared with the untreated I/R group
(12.62.03% vs 22.82.54%). Figure 1C shows that cerebral
blood ﬂow was signiﬁcantly reduced by >80% immediately
following occlusion of middle cerebral artery and complete
reperfusion was restored after the occlusion was released.
There was no signiﬁcant difference in cerebral blood ﬂow
between the CpG-ODN, control-ODN, iCpG-ODN, and the
untreated I/R groups.

CpG-ODN Administration Improved Neurological
Deﬁcits and Increased Survival Rate Following
Focal Cerebral I/R
Neurologic score evaluation is an index for the degree of
neurologic deﬁcits associated with ischemic stroke.9,30 We
evaluated the effect of CpG-ODN on neurological deﬁcits
following cerebral I/R. Figure 2A shows that the neurological
score was signiﬁcantly decreased in untreated I/R mice
following cerebral I/R for up to 4 days. In contrast, the
neurological scores in CpG-ODN-treated I/R mice were
signiﬁcantly greater than in the untreated I/R group at all
time periods. Administration of either control-ODN or iCpGODN did not markedly affect cerebral I/R-induced neurological deﬁcits.
We also evaluated the effect of CpG-ODN administration
on survival rate following cerebral I/R. As shown in Figure 2B,
in untreated mice, 50% of mice died at 48 hours and 80% died
at 96 hours following cerebral I/R. In CpG-ODN-treated mice,
however, 80% of mice survived at 96 hours and 50% survived
at 21 days after cerebral I/R. There was no signiﬁcant
difference in the survival rate between control-ODN, iCpGODN, and untreated I/R group.

CpG-ODN Administration Attenuated Neuronal
Damage in the Hippocampal Formation
We evaluated the effect of CpG-ODN administration on
neuronal morphology in the hippocampus after cerebral I/R.
Nissl staining showed that neuronal damage in the cormu
ammonis 1 (CA1) ﬁeld of the hippocampal formation (HF) is
characterized by shrunken cell bodies accompanied by
shrunken and pyknotic nuclei in the untreated I/R mice
(Figure 3). Similar morphological changes were observed in
the dentate gyrus (DG) ﬁeld. In CpG-ODN treated I/R mice,
neuronal damage in the HF was signiﬁcantly decreased and
morphology was preserved. Administration of control-ODN or
iCpG-ODN did not alter I/R-induced neuronal morphological
changes in the hippocampus (Figure 3).
Journal of the American Heart Association
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The cells were harvested for preparation of cellular proteins,
which were used for examination of Akt phosphorylation by
western blot. There were 6 replicates in each group.
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Figure 1. CpG-ODN administration reduces infarct volume following cerebral I/R. A, CpG-ODN (10 lg/

25 g body weight), control-ODN (10 lg/25 gam body weight) or iCpG-ODN (100 lg/25 g body weight)
was administered to mice, respectively, by i.p. injection 1 hour prior to cerebral ischemia (n=8/group). B,
CpG-ODN (10 lg/25 g body weight) was given to mice 15 minutes after ischemia by intravascular
injection. Mice were subjected to cerebral ischemia (60 minutes) followed by reperfusion (24 hours).
Representative image of infarct size from groups are shown on the top of bar graph (n=8 in untreated and
n=6 in post treated group). C, Cerebral blood ﬂow measurement before, during and after ischemia (n=6 in
untreated, n=6 in CpG-ODN, n=7 in iCpG, and n=6 in control ODN group). *P<0.05 compared with indicated
group. CBF indicates cerebral blood ﬂow; ODN, oligodeoxynucleotide.

CpG-ODN Administration Attenuated Apoptosis in
the Brain Following Cerebral I/R Injury
Cerebral I/R-induced apoptosis plays a role in brain tissue
injury in response to I/R.35 We examined whether administration of CpG-ODN will attenuate cerebral I/R-induced
apoptosis in the brain tissues. TUNEL assay showed that
cerebral I/R signiﬁcantly induced apoptosis in the ﬁelds of
DOI: 10.1161/JAHA.113.000629

CA1 and cortex (Figure 4A). In CpG-ODN treated I/R mice,
however, the numbers of apoptotic nuclei were signiﬁcantly
reduced by 78.8% in CA1 region and by 91.7% in the cortex,
respectively, when compared with untreated I/R mice.
Cerebral I/R also signiﬁcantly induced caspase-3 activity as
evidenced by showing positive ﬂuorescent staining with a
speciﬁc anti-cleaved caspase-3 antibody (Figure 4B), when
compared with sham control. Caspase-3/7 activity was also
Journal of the American Heart Association
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Bcl-2 is important for cell survival and anti-apoptosis while
Bax promotes apoptosis.36 We examined the effect of CpGODN administration on the levels of Bcl2 and Bax in the
brain tissues following cerebral I/R. As shown in Figure 4D
and 4E, cerebral I/R increased the levels of Bax by 126.7%
in the brain tissues compared with sham control. In
contrast, CpG-ODN administration prevented I/R-increased
Bax levels in the brain tissues. CpG-ODN treatment also
signiﬁcantly increased Bcl2 levels by 41% in the brain
tissues following cerebral I/R compared with untreated I/R
mice (1.240.10 vs 0.880.14). Administration of
either control-ODN or iCpG-ODN to mice did not
affect the levels of Bax and Bcl2 in the brain tissues
following I/R.

CpG-ODN Administration Attenuated Cerebral
I/R-Induced Microglial Cell Activation

Downloaded from http://ahajournals.org by on March 29, 2022

Figure 2. CpG-ODN treatment improved neurological deﬁcits
and increased survival rate following cerebral I/R. Mice were
treated with CpG-ODN, or control-ODN, or iCpG-ODN, respectively, 1 hour prior to cerebral ischemia (60 minutes) followed by
reperfusion for up to 4 to 21 days. Untreated I/R served as I/R
control. Sham operation served as sham control. A, Neurological
function was evaluated using a scoring system ranging 0 to 15,
with 15 being a perfect score and 0 being death due to cerebral I/
R injury (n=7 in untreated, n=8 in CpG, n=7 in iCpG, n=7 in
control ODN group). B, Survival rate was evaluated following
cerebral I/R (n=16 in untreated, n=14 in CpG, n=14 in iCpG, and
n=15 in control ODN group). *P<0.05 compared with indicated
group. I/R indicates ischemia/reperfusion; ODN, oligodeoxynucleotide.

signiﬁcantly increased in the brain tissues following cerebral
I/R (Figure 4C). In contrast, CpG-ODN administration markedly reduced the numbers of positive ﬂuorescent staining
cells and attenuated caspase-3/7 activity, when compared
with untreated I/R group. Treatment of mice with controlODN or iCpG-ODN did not signiﬁcantly alter cerebral I/R
induced apoptosis and caspase-3/7 activity in the brain
tissues.
DOI: 10.1161/JAHA.113.000629

Microglia are active sensor and effector cells in the
pathophysiological brain injury.37 We have previously
reported that cerebral I/R induced microglia activation in
brain tissues.30 We examined whether CpG-ODN administration will attenuate cerebral I/R-induced microglial cell
activation. Figure 5 shows that cerebral I/R induced microglial cell activation as evidenced by anti-Iba-1 positive staining
cells in the cortex region of brain (green color). I/R also
induced caspase-3 activity (red color) in microglial cells
(yellow color in merge). In CpG-ODN treated mice, however,
the numbers of anti-Iba-1 positive staining cells were
signiﬁcantly decreased compared with untreated I/R mice
(52.23.8% vs 74.93%). CpG-ODN administration also
markedly reduced caspase-3 activity in microglial cells.
Administration of either control-ODN or iCpG-ODN did not
markedly alter I/R-induced activation of microglial cells and
caspase-3 activity in microglial cells.

CpG-ODN Treatment Increased the Levels of
Phospho-Akt and Phospho-GSK-3b in the Brain
Tissues
Activation of the PI3K/Akt signaling pathway induces protection against cerebral I/R.30,38 We examine the effect of CpGODN on the activation of PI3K/Akt signaling in the brain
tissues. Figure 6A shows that CpG-ODN treatment signiﬁcantly increased the levels of phospho-Akt in the brain tissues
of sham control mice. Cerebral I/R increased the levels of
phospho-Akt compared with sham control. However, the
levels of phospho-Akt in CpG-ODN treated mice were further
Journal of the American Heart Association
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CpG-ODN Administration Increased Bcl-2 and
Attenuated Bax Levels in Brain Tissues Following
Cerebral I/R
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Figure 3. CpG-ODN treatment attenuated neuronal damage in the HF following cerebral I/R. Mice were
treated with CpG-ODN, or control-ODN, or iCpG-ODN, respectively, 1 hour prior to cerebral ischemia
(60 minutes) followed by reperfusion for 24 hours. Sham operation served as sham control. Brains were
harvested, sectioned, and stained with 0.1% cresyl violet (n=4 in each group). HF indicates hippocampal
formation; ODN, oligodeoxynucleotide.

increased following cerebral I/R, when compared with
untreated I/R group.
GSK-3b is an important downstream target of Akt.26
Figure 6B shows that CpG-ODN administration markedly
DOI: 10.1161/JAHA.113.000629

increased the levels of phospho-GSK-3b in sham control
mice. The levels of phospho-GSK-3b in CpG-ODN treated mice
were further increased following cerebral I/R compared with
untreated I/R group. Treatment of mice with either controlJournal of the American Heart Association
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Figure 4. CpG-ODN administration attenuated I/R-induced apoptosis in brain tissues. Mice were treated with CpG-ODN, or control-ODN, or
iCpG-ODN, respectively, 1 hour prior to cerebral ischemia (60 minutes) followed by reperfusion for 24 hours (n=6/group). Sham surgical
operation served as sham control (n=4). Brains were harvested and sectioned. Cellular proteins were prepared from the remaining brain
tissues. A, Apoptosis in brain tissue were examined by TUNEL assay (n=3/group) and (B) caspase-3 activity was stained by cleaved caspase-3
antibody (red). The nuclei were stained by DAPI (blue). C, Caspase-3/7 activity was measured using Caspase-Glo 3/7 assay kit. D and E, CpGODN decreased Bax (D) and increased Bcl2 (E) levels in the brain tissues following cerebral I/R. *P<0.05 compared with indicated groups.
GAPDH indicates glyceraldehyde-3-phosphate dehydrogenase; I/R indicates ischemia/reperfusion; ODN, oligodeoxynucleotide; TUNEL, TdTmediated dUTP nick end-labeling.
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Figure 5. CpG-ODN administration attenuated I/R-induced caspase-3 activity in microglial cells in the
brain tissues. Mice were treated with CpG-ODN, or control-ODN, or iCpG-ODN, respectively, 1 hour prior to
cerebral ischemia (60 minutes) followed by reperfusion for 24 hours. Sham surgical operation served as
sham control. Brains were harvested and sectioned. Activation of microglia was examined with speciﬁc
antibody against Iba1 (green) and caspase-3 activity was measured by anti-cleaved-caspase-3 antibody
(red). Nuclei were stained with DAPI (blue). Caspase-3 activity in activated microglial cells were yellow color
(merge). (n=3/group). I/R indicates ischemia/reperfusion; ODN, oligodeoxynucleotide.

ODN or iCpG-ODN did not signiﬁcantly alter the levels of
phospho-Akt and phosopho-GSK-3b in the brain tissues with
and without cerebral I/R.

CpG-ODN Induced Akt and GSK Phosphorylation
in Cultured Microglial Cells
We performed in vitro experiments using microglial cells (BV2)
to investigate whether CpG-ODN can activate PI3K/Akt
signaling. BV2 cells were treated with CpG-ODN for 0, 15,
30, and 60 minutes, respectively. Control-ODN served as
control. Figures 6C and 6D show that CpG-ODN treatment
DOI: 10.1161/JAHA.113.000629

signiﬁcantly induced Akt (C) and GSK-3b (D) phosphorylation
at 30 and 60 minutes, compared with the untreated group.
PI3K inhibition by LY294002 completely prevented CpG-ODNinduced Akt phosphorylation (Figure 6E). Control-ODN did not
markedly stimulate Akt and GSK-3b phosphorylation in
microglial cells.

Inhibition of PI3K/Akt Abolished CpG-ODNInduced Protection Against Cerebral I/R Injury
To determine whether activation of PI3K/Akt signaling
contributes to CpG-ODN induced protection against cerebral
Journal of the American Heart Association
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Figure 6. CpG-ODN administration increases levels of Akt and GSK-3b phosphorylation in the brain tissues and in
cultured microglial cells. Mice were treated with CpG-ODN (n=7), or control-ODN (n=7), or iCpG-ODN (n=6),
respectively, 1 hour prior to cerebral ischemia (60 minutes) followed by reperfusion (24 hours). Untreated I/R mice
served as I/R control (n=6). Sham surgical operation served as sham control (n=4). Brains were harvested and
cellular proteins were prepared. The phospho-Akt (A) and phospho-GSK-3b (B) were examined by Western blot with
speciﬁc antibodies. C and D, Microglial cells (BV2) were treated with CpG-ODN or control-ODN for 15, 30, and
60 minutes. The cells were harvested and cellular proteins were prepared Western blot examination of (C) Akt and
(D) GSK-3b phosphorylation. E, Microglial cells (BV2) were treated with CpG-ODN for 15, 30, and 60 minutes in the
presence and absence of LY294002. PI3K inhibition by LY294002 prevents CpG-ODN-induced Akt phosphorylation in
cultured microglial cells (n=6 replicates/group). *P<0.05 compared with indicated groups. GSK indicates glycogen
synthase kinase; ODN, oligodeoxynucleotide.
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inhibition of PI3K abrogates
CpG-ODN induced protection against cerebral I/R injury. Mice
were treated with or without LY294002 (1 mg/25 g body weight)
15 minutes before administration of CpG-ODN. The mice were
subjected to cerebral ischemia (60 minutes) followed by reperfusion (24 hours). LY294002 was also administered to mice
15 minutes prior to I/R. Infarct size was examined by TTC
staining. n=8/group. *P<0.05 compared with indicated groups. I/
R indicates ischemia/reperfusion; ODN, oligodeoxynucleotide.
Downloaded from http://ahajournals.org by on March 29, 2022

I/R injury, we treated mice with LY294002, a speciﬁc PI3K
inhibitor,20,23,30 15 minutes prior to CpG-ODN administration.
As shown in Figure 7, CpG-ODN administration markedly
reduced infarct volume compared with untreated I/R mice.
However, the infarct volume in CpG-ODN treated mice was
comparable with untreated I/R mice, when LY294002 was
administered. Thus, PI3K/Akt inhibition by LY294002 completely abolished protection against cerebral I/R injury by CPGODN. There was no signiﬁcant difference in the infarct volume
between CpG-ODN-LY294002 I/R group and untreated I/R
mice. Figures 6A and 6B show that LY294002 treatment
prevented CpG-ODN-induced increases in the levels of
phospho-Akt and phospho-GSK-3b in the brain tissues.

Discussion
The present study has shown that administration of CpGODN, a TLR9 ligand, to mice 1 hour prior to cerebral I/R
signiﬁcantly reduced infarct volume, attenuated neurological
deﬂects and improved survival rate following cerebral I/R
injury. More signiﬁcantly, therapeutic administration of CpGODN, 15 minutes after ischemia, also markedly decreased
cerebral I/R-induced infarct volume. In addition, CpGODN administration signiﬁcantly increased the levels of
DOI: 10.1161/JAHA.113.000629
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phospho-Akt and phospho-GSK3b in the brain tissues. PI3K
inhibition abolished CpG-ODN-induced protection against
cerebral I/R injury. Thus our data suggest that CpG-ODN
attenuates focal cerebral I/R injury via a PI3K/Akt dependent mechanism.
Innate immune and inﬂammatory responses are known to
be involved in cerebral I/R injury.2–4 TLRs play a critical role in
the induction of innate immune responses.5 TLRs activate
signaling through MyD88 and/or TRIF.5 Recent evidence has
indicated that TLRs contribute to cerebral I/R injury.6,10–12,39
For example, TLR4 deﬁciency protects the brain from cerebral
I/R injury.6,10–12,39 Hua et al reported that MyD88 or TRIF
knockout mice did not show a reduction of cerebral infarction
or improvement of neurological deﬁcits following cerebral
I/R.40,41 This observation indicated that the signaling mediated by MyD88 or TRIF may be required for protection. Indeed,
we have previously reported that modulation of TLR2 by its
ligand, Pam3CSK4 signiﬁcantly reduced infarct volume and
improved neurological score following cerebral I/R injury.30
Recently Stevens et al reported that activation of TLR9 by its
agonist, CpG-ODN, signiﬁcantly induced protection against
ischemic stroke.14 Hyakkoku et al reported that TLR3 or TLR9
deﬁciency did not show a neuroprotective effect against
cerebral I/R,42 indicating that TLR3 or TLR9 may serve a
protective role in cerebral I/R injury. Indeed, we demonstrated
in the present study that administration of CpG-ODN
decreased infarct volume and improved neurological score
following cerebral I/R. We also observed that therapeutic
administration of CpG-ODN decreased infarct volume. Collectively, the data suggest that modulation of TLR9 by its ligand
CpG-ODN could be an approach for the treatment and
management of ischemic stroke.
Cerebral I/R induces neuronal apoptosis, which contributes to brain injury in response to I/R.35 It is well known that
Bax is a pro-apoptotic molecule whereas Bcl2 is an important
anti-apoptotic molecule.36 We observed that cerebral I/R
signiﬁcantly increased the levels of Bax and caspase-3/7
activity in the brain tissues, which are consistent with the data
showing cerebral I/R, induced apoptotic cells in the brain
tissues. Importantly, CpG-ODN administration signiﬁcantly
decreased I/R-induced apoptosis and attenuated I/Rincreased levels of Bax and caspase-3/7 activity in the brain
tissues. In addition, CpG-ODN markedly increased the levels
of Bcl2 both in sham control and I/R mice. The data indicate
that the anti-apoptotic effect of CpG-ODN43 may be one of the
mechanisms by which CpG-ODN attenuated cerebral I/R
injury.
Microglia are active sensors and versatile effector cells in
pathological and pathophysiological brain injury.37 Interestingly, a recent study by Burguillos et al reported that
activation of caspase-8 is associated with microglial activation.44 Activated microglia release substances that cause

CpG-ODN Decreases Cerebral Ischemic Injury

Lu et al.

DOI: 10.1161/JAHA.113.000629

Sources of Funding
This work was supported, in part, by NIH HL071837 to Li, NIH
GM083016 to Li and Williams, NIH GM53522 to Williams.

Disclosures
None.

References
1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G,
Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern
S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A,
McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger V,
Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S,
Wong ND, Wylie-Rosett J; The American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—
2010 update. Circulation 2010; 121:e1–e170.
2. Wang Q, Tang XN, Yenari MA. The inﬂammatory response in stroke.
J Neuroimmunol. 2007;184:53–68.
3. Stoll G. Inﬂammatory cytokines in the nervous system: multifunctional
mediators in autoimmunity and cerebral ischemia. Rev Neurol. 2002;158:887–
891.
4. del Zoppo GJ. Acute anti-inﬂammatory approaches to ischemic stroke. Ann NY
Acad Sci. 2010;1207:143–148.
5. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the
Drosophila Toll protein signals activation of adaptive immunity. Nature.
1997;388:394–397.
6. Caso J, Pradillo J, Hurtado O, Lorenzo P, Moro M, Lizasoain I. Toll-like receptor
4 is involved in brain damage and inﬂammation after experimental stroke.
Circulation. 2007;115:1599–1608.
7. Tang SC, Arumugam TV, Xu X, Cheng A, Hughal MR, Jo DG, Lathia JD, Siler DA,
Chigurapati S, Ouyang X, Magnus T, Camadola S, Mattson MP. Pivotal role for
neuronal Toll-like receptors in ischemic brain injury and functional deﬁcits.
Proc Natl Aad Sci USA. 2007;104:13798–13803.
8. Hua F, Ma J, Ha T, Xia Y, Kelley J, Williams DL, Kao RL, Browder IW, Schweitzer
JB, Kalbﬂeisch JH, Li C. Activation of Toll-like receptor 4 signaling contributes
to hippocampal neuronal death following global cerebral ischemia/reperfusion. J Neuroimmunol. 2007;190:101–111.
9. Hua F, Ma J, Ha T, Kelley J, Williams DL, Kao RL, Kalbﬂeisch JH, Browder IW, Li
C. Preconditioning with a TLR2 speciﬁc ligand increases resistance to cerebral
ischemia/reperfusion injury. J Neuroimmunol. 2008;199:75–82.
10. Hua F, Ma J, Ha T, Kelley JL, Kao RL, Schweitzer JB, Kalbﬂeisch JH, Williams DL,
Li C. Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/
reperfusion injury in mice. Brain Res. 2009;1262:100–108.
11. Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S, Kreuger C,
Nitsch R, Meisel A, Weber JR. Toll-like receptor 2 mediates CNS injury in focal
cerebral ischemia. J Neuroimmunol. 2007;190:28–33.
12. Ziegler G, Harhausen D, Schepers C, Hoffmann O, Rohr C, Prinz V, Konig J,
Lehrach H, Nietfeld W, Trendelenburg G. TLR2 has a detrimental role in mouse
transient focal cerebral ischemia. Biochem Biophys Res Commun.
2007;359:574–579.
13. Marsh B, Stevens SL, Packard AEB, Gopalan B, Hunter B, Leung PY, Harrington
CA, Stenzel-Poore MP. Systemic lipopolysaccharide protects the brain from
ischemic injury by reprogramming the response of the brain to stroke: a
critical role for IRF3. J Neurosci. 2009;29:9839–9849.
14. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule JL, Lessov NS,
Simon RP, Stenzel-Poore MP. Toll-like receptor 9: a new target of ischemic
preconditioning in the brain. J Cereb Blood Flow Metab. 2008;28:1040–1047.
15. Bahjat FR, Williams-Karnesky RL, Kohama SG, West GA, Doyle KP, Spector MD,
Hobbs TR, Stenzel-Poore MP. Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury
in a primate model of stroke. J Cereb Blood Flow Metab. 2011;31:1229–1242.
16. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of
DNA. Adv Drug Deliv Rev. 2008;60:795–804.
17. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug
Discov. 2006;5:471–484.
18. Sester DP, Brion K, Trieu A, Goodridge HS, Roberts TL, Dunn J, Hume DA,
Stacey KJ, Sweet MJ. CpG DNA activates survival in murine macrophages

Journal of the American Heart Association

12

ORIGINAL RESEARCH

Downloaded from http://ahajournals.org by on March 29, 2022

neuronal injury.37,45 We have observed that cerebral I/R
induces microglial activation in brain tissues. However, CpGODN treatment prevented I/R-induced activation of microglial
cells, suggesting that CpG-ODN can prevent microglial
activation. Microglial cells are responsible for much of the
TLR expression in brain tissue.45 We have previously reported
that TLR2 modulation increased PI3K/Akt signaling in
microglial cells.30 CpG-ODN treatment also increased the
levels of Akt and GSK-3b phosphorylation, which may be a
possible mechanism for preventing microglial activation by
CpG-ODN.
We observed in the present study that CpG-ODN administration signiﬁcantly induced Akt and GSK-3b phosphorylation both in vivo and in vitro, indicating that CpG-ODN can
activate the PI3K/Akt signaling pathway.20,30 We have
previously reported that activation of PI3K/Akt signaling
attenuates cerebral I/R-induced brain injury and neuronal
apoptosis,30 protects the myocardium from I/R injury20 and
improves outcome of polymicrobial sepsis.23 Activation of
PI3K/Akt signaling has been reported to protect cells from
apoptosis induced by I/R.27,33,46 Activated PI3K/Akt can
inhibit Bax conformational change, thus preventing Bax from
translocating and integrating into mitochondrial membranes.
PI3K/Akt activation also phosphorylates Bim, leading to
dissociation of Bim from Bcl2. In addition, activation of
PI3K/Akt may be a negative feedback regulator that
prevents excessive innate immune and/or inﬂammatory
responses.47,48
We have previously reported that treatment of cardiomyoblasts with CPG-ODN induced TLR9 tyrosine phosphorylation
followed by association with the p85 subunit of PI3K,20,23
resulting in activating PI3K/Akt signaling. We have observed
in the present study that CpG-ODN-induced activation of
PI3K/Akt signaling both in vivo and in vitro cultured microglial
cells, indicating that activation of the PI3K/Akt signaling
pathway may contribute to the CpG-ODN-induced protective
effect against cerebral I/R injury. To evaluate our hypothesis,
we treated mice with a PI3K speciﬁc inhibitor, LY294002,
before CpG-ODN administration. We observed that PI3K
inhibition completely abolished CpG-ODN-induced protection
against cerebral I/R injury. The data suggests that CpG-ODNinduced protection against cerebral is mediated via the PI3K/
Akt dependent mechanisms.
In summary, administration of CpG-ODN signiﬁcantly
decreased I/R-induced infarct volume and improved neurological score following cerebral I/R. Therapeutic administration of CpG-ODN also markedly reduced I/R-induced infarct
volume. CpG-ODN-induced protection against cerebral I/R
injury is mediated through activation of PI3K/Akt signaling.
The data suggest that the CpG-ODN may be a new
approach for the management and treatment of cerebral
I/R injury.

CpG-ODN Decreases Cerebral Ischemic Injury

Lu et al.

19. Mathur S, Walley KR, Boyd JH. The Toll-like receptor 9 ligand CPG-C attenuates
acute inﬂammatory cardiac dysfunction. Shock. 2011;36:478–483.
20. Cao Z, Ren D, Ha T, Liu L, Wang X, Kalbﬂeisch J, Gao X, Kao R, Williams D, Li C.
CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion
injury: Involving activation of PI3K/Akt signaling. Biochim Biophys Acta.
2013;1832:96–104.
21. Rice L, Orlow D, Ceonzo K, Stahl GL, Trianabos AO, Wada H, Aird WC, Buras JA.
CpG oligodeoxynucleotide protection in polymicrobial sepsis is dependent on
interleukin-17. J Infect Dis. 2005;191:1368–1376.
22. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B.
Increased resistance against acute polymicrobial sepsis in mice challenged
with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced
innate effector cell response. J Immunol. 2000;165:4537–4543.
23. Gao M, Ha T, Zhang X, Lam F, Wang X, Kelley JL, Singh K, Kalbﬂeisch J, Kao R,
Williams DL, Li C. The TLR9 ligand, CPG-ODN, attenuates cardiac dysfunction
in polymicrobial sepsis via activation of PI3K/AKT and ERK signaling
pathways. Shock. 2012;37:33.
24. Zhang X, Gao M, Ha T, Kalbﬂeisch JH, Browder W, Williams DL, Li C, Kao RL.
The TLR9 agonist, CpG-ODN 1826, ameliorates cardiac dysfunction after
trauma-hemorrhage. Shock. 2012;38:146–152.
25. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in
medicine: therapeutic applications and developments. Clin Pharmacol Ther.
2008;83:761–769.
26. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:
1655–1657.
27. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of
cardiomyocytes in vitro and protects against ischemia-reperfusion injury in
mouse heart. Circulation. 2000;101:660–667.
28. Matsui T, Ling L, del Monte F, Fukui Y, Franke TF, Hajjar RJ, Rosenzweig A.
Adenoviral gene transfer of activated phosphatidylinositol 3’ -kinase and akt
inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation.
1999;100:2373–2379.
29. Ojaniemi M, Glumoff V, Harju K, Liljeroos M, Vuori K, Hallman M.
Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated
cytokine expression in mouse macrophages. Eur J Immunol. 2003;33:
597–605.

Downloaded from http://ahajournals.org by on March 29, 2022

30. Lu C, Liu L, Chen Y, Ha T, Kelley J, Schweitzer J, Kalbﬂeisch JH, Kao RL,
Williams DL, Li C. TLR2 ligand induces protection against cerebral ischemia/
reperfusion injury via activation of phosphoinositide 3-kinase/Akt signaling.
J Immunol. 2011;187:1458–1466.
31. Lu C, Hua F, Liu L, Ha T, Kalbﬂeisch J, Schweitzer J, Kelley J, Kao R, Williams D,
Li C. Scavenger receptor class-A has a central role in cerebral ischemia/
reperfusion injury. J Cereb Blood Flow Metab. 2010;30:1972–1981.
32. Yang L, Guo W, Zhang Q, Li H, Liu X, Yang Y, Zuo J, Liu W. Crosstalk between
Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by
Grp75 under glucose deprivation conditions. J Mol Biol. 2011;414:654–666.

DOI: 10.1161/JAHA.113.000629

33. Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, Browder W, Williams DL. Modulating
Toll-like receptor mediated signaling by (1–>3)-b-D-glucan rapidly induces
cardioprotection. Cardiovasc Res. 2003;61:538–547.
34. Ha T, Hu Y, Liu L, Lu C, McMullen JR, Shioi T, Isumo S, Kelley J, Kao RL,
Williams DL, Gao X, Li C. TLR2 ligands induce cardioprotection against
ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism.
Cardiovasc Res. 2010;87:694–703.
35. Broughton BRS, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral
ischemia. Stroke. 2009;40:e331–e339.
36. Herrmann JL, Beham AW, Sarkiss M, Chiao PJ, Rands MT, Bruckheimer EM,
Brisbay S, McDonnell TJ. Bcl-2 suppresses apoptosis resulting from disruption
of the NF-kappa B survival pathway. Exp Cell Res. 1997;237:101–109.
37. Weinstein JR, Koerner IP, Moller T. Microglia in ischemia brain injury. Future
Neurol. 2010;5:227–246.
38. Zhao H, Sapolsky RM, Steinberg GK. Phosphoinositide-3-kinase/akt survival
signal pathways are implicated in neuronal survival after stroke. Mol Neurobiol.
2006;34:249–270.
39. Cao CX, Yang QW, Ly FL, Cui J, Fu HB, Wang JZ. Reduced cerebral ischemiareperfusion injury in Toll-like receptor 4 deﬁcient mice. Biochem Biophys Res
Comm. 2006;353:509–514.
40. Hua F, Wang J, Sayeed I, Ishrat T, Atif F, Stein DG. The TRIF-dependent
signaling pathway is not required for acute cerebral ischemia/reperfusion
injury in mice. Biochem Biophys Res Commun. 2009;390:678–683.
41. Yang QW, Li JC, Lu FL, Wen AQ, Xiang J, Zhang LL, Huang ZY, Wang JZ.
Upregulated expression of toll-like receptor 4 in monocytes correlates with
severity of acute cerebral infarction. J Cereb Blood Flow Metab. 2008;28:
1588–1596.
42. Hyakkoku K, Hamanaka J, Tsuruma K, Shimazawa M, Tanaka H, Uematsu S,
Akira S, Inagaki N, Nagai H, Hara H. Toll-like receptor 4 (TLR4), but not TLR3 or
TLR9, knock-out mice have meuroprotective effects against focal cerebral
ischemia. Neuroscience. 2010;171:258–267.
43. Lim EJ, Park DW, Jeong TW, Chin BR, Bae YS, Baek SH. TRAIL is involved in CpG
ODN-mediated anti-apoptotic signals. Oncol Rep. 2012;27:1213–1218.
44. Burguillos MA, Dejerborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla
A, Cano J, Brundin P, Englund E, Venero JL, Joseph B. Caspase signalling
controls microglia activation and neurotoxicity. Nature. 2011;472:319–324.
45. Olson JK, Miller SD. Microglia initiate central nervous system innate and
adaptive immune responses through multiple TLRs. J Immunol. 2004;173:
3916–3924.
46. Zhou H, Li X-M, Meinkoth J, Pittman RN. Akt regulates cell survival and
apoptosis at a postmitochondrial level. J Cell Biol. 2000;151:483–494.
47. Fukao T, Koyasu S. PI3K and negative regulation of TLR signaling. Trends
Immunol. 2003;24:358–363.
48. Ha T, Hua F, Liu X, Ma J, McMullen JR, Shioi T, Izumo S, Kelley J, Gao X,
Browder W, Williams DL, Kao RL, Li C. Lipopolysaccharide-induced myocardial
protection against ischemia/reperfusion injury is mediated through a PI3K/
Akt-dependent mechanism. Cardiovasc Res. 2008;78:546–553.

Journal of the American Heart Association

13

ORIGINAL RESEARCH

through TLR9 and the phosphatidylinositol 3-kinase-akt pathway. J Immunol.
2006;177:4473–4480.

